Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05573607
Other study ID # 25-CAHS-104
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 19, 2020
Est. completion date July 8, 2021

Study information

Verified date November 2022
Source The Center for Applied Health Sciences, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a double-blind, randomized, two-arm, placebo-controlled trial of apparently healthy men and women to be recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences). Subjects will attend four study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work [also HgA1c, insulin], background baseline diet). Over the next 12 weeks, subjects will attend Visits 2-4, wherein assessments of serum glucose, insulin, HOMA-IR, 2-hour glucose tolerance test (GTT), HgA1c, C-reactive protein, adiponectin, ferritin, waist circumference, quality of life questionnaire, and various visual analog scales for appetite, satiety, and cravings will be made.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date July 8, 2021
Est. primary completion date July 8, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: Provide voluntary signed and dated informed consent. Be in good health as determined by medical history and routine blood chemistries. Age between the ages of 21 and 65 (inclusive). Body Mass Index of 18.5-34.99 (inclusive). Body weight of at least 120 pounds. Fasting blood sugar of 100-125 (inclusive) OR HgA1c of 5.7-6.4% (inclusive). Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic bloodpressure < 90 mm Hg. Normal seated, resting heart rate (<90 per minute). Willing to duplicate their previous 24-hour diet, refrain from caffeine for 12 hrs and exercise for 24 hr prior to each trial, and fast for 10 hours prior each of the treatments. Exclusion Criteria: History of unstable or new-onset cardiovascular or cardiorespiratory disease. History of diabetes, or other endocrine disorder. Fasting blood sugar of > 125 mg/dL or HgA1c of > 6.4%. History of use of medications or dietary supplements known to affect glycemia or insulinemia. History of hyperparathyroidism or an untreated thyroid disease. History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). Prior gastrointestinal bypass surgery (Lapband), etc. Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU). Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of- Analysis. Currently participating in another research study with an investigational product or have been in another research study in the past 30 days. Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
Maltodextrin tablet
Chromium
A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)

Locations

Country Name City State
United States The Center for Applied Health Sciences Canfield Ohio

Sponsors (3)

Lead Sponsor Collaborator
The Center for Applied Health Sciences, LLC Keller Consulting Group, Mend Nutrition, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary glucose measurement of glucose in blood change from baseline to week 12
Primary insulin measurement of insulin in blood change from baseline to week 12
Secondary cravings cravings as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings. change from baseline to week 12
Secondary satiety satiety as measured with a 10 cm anchored visual analogue scale, where higher values represent greater cravings. change from baseline to week 12
Secondary adiponectin measurement of adiponectin in blood change from baseline to week 12
Secondary blood urea nitrogen measurement of blood urea nitrogen in blood change from baseline to week 12
Secondary creatinine measurement of creatinine in blood change from baseline to week 12
Secondary alanine aminotransferase measurement of alanine aminotransferase in blood change from baseline to week 12
Secondary aspartate aminotransferase measurement of aspartate aminotransferase in blood change from baseline to week 12
Secondary Short Form Health Survey (SF-36) health status as measured with the SF-36 questionnaire, where scores range from 0 to 100, and higher values represent better health status. change from baseline to week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04578067 - Empowering Immigrant Women for Active and Healthy Lifestyle N/A
Completed NCT04256746 - Dose Response Study of a Natural Extract for Reducing Post Prandial Blood Glucose N/A
Completed NCT03254082 - Glycemic Response of Sorghum N/A
Completed NCT02536066 - Daily Physical Activity After Meals -Long Term Effects on Blood Glucose N/A
Completed NCT00444171 - Glucose Control by eMPC Algorithm in Peri- and Postoperative Period in Cardiac Surgery Patients N/A
Completed NCT00302302 - The Effects of L-arabinose on Intestinal Sucrase Activity in Man Phase 1
Completed NCT04378374 - The Effect of Pulse Flours on Blood Glucose, Satiety and Food Intake N/A
Completed NCT04451655 - Glycemic Stability During the Intraoperative Period Among Patients With DM Undergoing CABG Surgery N/A
Recruiting NCT04989712 - MOReS Freestyle Libre Validation Study N/A
Completed NCT05352724 - Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise N/A
Completed NCT04260425 - A Pilot Study Evaluating Oat Polyphenols on Post-prandial Glucose Response N/A
Completed NCT04258501 - Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response N/A
Completed NCT02968498 - Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers N/A
Completed NCT02484313 - The Effect of Snacks on Glycaemic Regulation in Children N/A
Withdrawn NCT01246492 - The Effect of Artificial Sweeteners on Blood Glucose Response N/A
Completed NCT01241253 - Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus Phase 2
Completed NCT03914430 - Breakfast Cereals Consumed in Dairy and Non-dairy Medium: the Effects on Blood Glucose, Satiety and Food Intake N/A
Recruiting NCT05255783 - The Performance of Dexcom G6 Glucose Monitoring in Critically Ill Patients N/A
Recruiting NCT05585801 - Continuous Glucose Monitoring in Intensive Care Unit N/A
Active, not recruiting NCT03978104 - Impact of Okara and Bio-okara Food Product on Gut and Glycaemic Health in Middle-aged and Older Adults in Singapore N/A